Loading clinical trials...
Loading clinical trials...
The purpose of this study is to demonstrate the efficacy and safety of AR101 through oral immunotherapy (OIT) in peanut-allergic children.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Aimmune Therapeutics, Inc.
NCT05695261 · Allergy, Peanut, Peanut Allergy, and more
NCT03835767 · Milk and/or Peanut Allergy
NCT04222491 · Peanut Allergy
NCT04511494 · Peanut Allergy
NCT05424731 · Peanut Allergy
Unité de dermatologie Pédiatrique, Hôpital Pellegrin-Enfants, place Amélie Raba-Léon
Bordeaux
Hopital Saint Vincent de Paul, Service d'Allergologie
Lille
Paediatric Allergy and Pulmonology Center, Jeanne de Flandre Hospital, Lille University Hospital
Lille
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions